FindTrial
Sign In

Study on the prediction of efficacy and prognosis of neoadjuvant chemotherapy for breast cancer using breast ultrasound radiomics method

Study on the prediction of efficacy and prognosis of neoadjuvant chemotherapy for breast cancer using breast ultrasound radiomics method

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041653
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Histopathologic examination
Index test:Ultrasonic&#32
standard&#32
image

Sponsors

Ultrasonography Department, Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Female patients with breast cancer confirmed by histology and scheduled for NAC treatment; 2. Patients whose image quality meets the needs of diagnosis.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of breast surgery within one year; 2. Patients whose lesions are too large to envelope by ultrasound; 3. In the skin or skin surface lumps, foreign bodies, including prosthesis, vascular abnormalities, effusion and other patients.

Design outcomes

Primary

MeasureTime frame
Radiomics features;SEN, SPE, ACC, AUC of ROC, PV+, PV-;—

Countries

China

Contacts

Public ContactJie Li

Ultrasonography Department, Qilu Hospital of Shandong University

jieli301@163.com+86 18560081516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026